Publications by authors named "Jiwon Kong"

Article Synopsis
  • AIMP2-DX2 (DX2) is a variant of a protein linked to cancer, and reducing its levels can help stop tumor growth.
  • Researchers found that a compound called SDL01 enhances the interaction between DX2 and another protein, Siah1, promoting DX2's degradation.
  • SDL01 binds to a specific area on DX2, causing a change in its shape that strengthens its interaction with Siah1, showing that drug-induced changes can alter protein interactions.*
View Article and Find Full Text PDF

Microplastics (MPs) released from plastic products in daily life are present in the air and could be transported to freshwater environments along with rain. Recently, low-impact development (LID) facilities, such as permeable pavements, have been used to treat non-point source pollutants, including rainfall runoff. While runoff is treated by LID facilities, the periodic monitoring of MPs in rainfall and the efficiency of removal of MPs through LID facilities have rarely been investigated.

View Article and Find Full Text PDF

The serum level of CA 19-9 is a prognostic marker for pancreatic ductal adenocarcinoma (PDAC). We evaluated the ability of the expression level of methionyl-tRNA synthetase 1 (MARS1)-which facilitates cancer growth by modulating protein synthesis and the cell cycle-to predict the prognosis of PDAC. Immunohistochemical (IHC) staining was performed on pancreatic specimens obtained from patients with PDAC who were undergoing surgery.

View Article and Find Full Text PDF

Recent development of the chemical inhibitors specific to oncogenic KRAS (Kirsten Rat Sarcoma 2 Viral Oncogene Homolog) mutants revives much interest to control KRAS-driven cancers. Here, we report that AIMP2-DX2, a variant of the tumor suppressor AIMP2 (aminoacyl-tRNA synthetase-interacting multi-functional protein 2), acts as a cancer-specific regulator of KRAS stability, augmenting KRAS-driven tumorigenesis. AIMP2-DX2 specifically binds to the hypervariable region and G-domain of KRAS in the cytosol prior to farnesylation.

View Article and Find Full Text PDF

Although protein-protein interactions (PPIs) have emerged as an attractive therapeutic target space, the identification of chemicals that effectively inhibit PPIs remains challenging. Here, we identified through library screening a chemical probe (compound ) that can inhibit the tumor-promoting interaction between the oncogenic factor exon 2-depleted splice variant of aminoacyl-transfer RNA synthetase-interacting multifunctional protein 2 (AIMP2-DX2) and heat shock protein 70 (HSP70). We found that compound binds to the N-terminal subdomain of glutathione -transferase (GST-N) of AIMP2-DX2, causing a direct steric clash with HSP70 and an intramolecular interaction between the N-terminal flexible region and the GST-N of AIMP2-DX2, which induces masking of the HSP70 binding region during molecular dynamics and mutation studies.

View Article and Find Full Text PDF

In mammals, eight aminoacyl-tRNA synthetases (AARSs) and three AARS-interacting multifunctional proteins (AIMPs) form a multi-tRNA synthetase complex (MSC). MSC components possess extension peptides for MSC assembly and specific functions. Human cytosolic methionyl-tRNA synthetase (MRS) has appended peptides at both termini of the catalytic main body.

View Article and Find Full Text PDF

Cytoplasmic aminoacyl-tRNA synthetases (ARSs) are organized into multi-tRNA synthetase complexes (MSCs), from Archaea to mammals. An evolutionary conserved role of the MSCs is enhancement of aminoacylation by forming stable associations of the ARSs and tRNAs. In mammals, a single macromolecular MSC exists, which is composed of eight cytoplasmic ARSs, for nine amino acids, and three scaffold proteins.

View Article and Find Full Text PDF
Article Synopsis
  • - AIMP2-DX2, a variant of the AIMP2 protein, is found to be elevated in lung cancer and plays a role in tumor development, making it a target for cancer treatment.
  • - New small molecule inhibitors that disrupt the interaction between AIMP2-DX2 and HSP70 have been optimized, showing significantly improved effectiveness compared to earlier versions.
  • - One particular compound demonstrated strong cancer cell death induction in laboratory tests and showcased promising results in mouse models, indicating its potential as a new therapeutic option for lung cancer.
View Article and Find Full Text PDF

Although abnormal increases in the level or activity of cyclin-dependent kinase 4 (CDK4) occur frequently in cancer, the underlying mechanism is not fully understood. Here, we show that methionyl-tRNA synthetase (MRS) specifically stabilizes CDK4 by enhancing the formation of the complex between CDK4 and a chaperone protein. Knockdown of MRS reduced the CDK4 level, resulting in G0/G1 cell cycle arrest.

View Article and Find Full Text PDF

Aminoacylation has been implicated in a wide variety of cancers. Aminoacyl-tRNA synthetases (ARSs) exist in large excess in tumor cells due to their increased demand for translation, whereas most other protein-synthesis apparatuses are quantitatively limited. Among other components that constitute the translation machinery-namely, tRNA, amino acid, ATP, and ARS-ARS is the only target that can be blocked by small molecules.

View Article and Find Full Text PDF

While transfer-RNAs (tRNAs) are known to transport amino acids to ribosome, new functions are being unveiled from tRNAs and their fragments beyond protein synthesis. Here we show that phosphorylation of 90-kDa RPS6K (ribosomal proteins S6 kinase) was enhanced by tRNA overexpression under amino acids starvation condition. The phosphorylation of 90-kDa RPS6K was decreased by siRNA specific to tRNA and was independent to mTOR (mammalian target of rapamycin) signaling.

View Article and Find Full Text PDF

The RNA polymerase II (RNApII) C-terminal domain (CTD)-interacting domain (CID) proteins are involved in two distinct RNApII termination pathways and recognize different phosphorylated forms of CTD. To investigate the role of differential CTD-CID interactions in the choice of termination pathway, we altered the CTD-binding specificity of Nrd1 by domain swapping. Nrd1 with the CID from Rtt103 (Nrd1(CID(Rtt103))) causes read-through transcription at many genes, but can also trigger termination where multiple Nrd1/Nab3-binding sites and the Ser(P)-2 CTD co-exist.

View Article and Find Full Text PDF